Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial
6 affiliations
- 1Department of Pharmacy Practice, Center of Excellence in Bioactive Resources for Innovative Clinical Applications, Faculty of Pharmaceutical Sciences, Chulalongkorn University
- 2Center of Excellence in Nanomedicine, Faculty of Medicine, Chulalongkorn University
- 3Department of Internal Medicine, Police General Hospital
- 4Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Malaya KualaLumpur
- 5The Academy of Science, The Royal Society of Thailand
- 6Faculty of Pharmacy, Silpakorn University
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, chronic inflammation, and oxidative stress, leading to progressive functional impairment and reduced quality of life. Beta-glucan possesses immunomodulatory and anti-inflammatory properties, but its therapeutic potential in COPD remains poorly defined. This study aimed to optimize a combined formulation of beta-glucan, broccoli extract, and quercetin (Pro β-Glucan+) through in vitro evaluation and to investigate its clinical efficacy in patients with stable COPD.
Methods: HFL1 lung fibroblasts were treated with different ratios of Pro β-Glucan+®, and cell viability and wound healing assays were performed to identify the optimal formulation. The selected ratio was evaluated in a 12-week randomized, double-blind, placebo-controlled trial. A total of 42 participants were randomized, of whom 38 completed the study and were included in the final analysis (Pro β-Glucan+, n = 19; placebo, n = 19). Prespecified primary outcome was FEV ₁ . Secondary outcomes included clinical symptoms, functional capacity, health status, inflammatory and oxidative stress biomarkers, and patient satisfaction.
Results: The 10:3:2 ratio (beta-glucan:broccoli extract:quercetin) significantly enhanced HFL1 cell cell viability and wound healing activity among the tested formulations and was selected for clinical evaluation. Pro β-Glucan+® was well tolerated and associated with within-group improvements in dyspnea, respiratory symptoms, functional capacity, and health status after 12 weeks, with significant between-group differences in mMRC and CAT scores at week 12. No significant within- or between-group difference was observed in the prespecified primary outcome, FEV ₁ , or in systemic inflammatory and oxidative stress biomarkers. Patient satisfaction was higher with Pro β-Glucan+® than with placebo.
Conclusion: The optimized Pro β-Glucan+® formulation demonstrated in vitro biological activity and was associated with improvements in several clinical outcomes in patients with stable COPD. Significant between-group differences were observed in mMRC and CAT scores at week 12. These findings support further investigation of this combination as an adjunctive nutritional intervention for COPD management.
Clinical Trial Registration: https://clinicaltrials.gov/study/NCT05878834 , identifier NCT05878834.
Related
- Comparative evaluation of the antipyretic and analgesic efficacy and safety of a fast-release paracetamol 650 mg formulation vs. conventional paracetamol formulations in adults with acute febrile or febrile-pain conditions: a multicenter randomized controlled trial
- Effects of a hand sanitizer formulation on upper respiratory symptoms and work restrictions: a double-blind household cluster-randomized controlled trial
- Optimized Nutri-Dense meals versus a low-carbohydrate high-fat diet: an exploratory randomized controlled trial
- A Dual-Species Plant-derived Extracellular Vesicle and Growth Factors Formulation for Hair and Scalp Care: A Randomized, Placebo-controlled Study
- Efficacy of a Limosilactobacillus reuteri DSM 17938 and BG-R46® Formulation in Predominantly Breastfed Infants with Infant Distress Syndrome: A Randomized Double-Blind Placebo-Controlled Trial
BibTeX
@article{napavichayanun2026effects,
title = {{Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial}},
author = {Supamas Napavichayanun and Rungnapha Yamdech and Sarocha Cherdchom and Apisara Suriyakul and Tippawan Phetngam and Syed Mahmood and Pornanong Aramwit},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1938897},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1938897/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial
AU - Supamas Napavichayanun
AU - Rungnapha Yamdech
AU - Sarocha Cherdchom
AU - Apisara Suriyakul
AU - Tippawan Phetngam
AU - Syed Mahmood
AU - Pornanong Aramwit
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1938897
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1938897/full
AB - Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, chronic inflammation, and oxidative stress, leading to progressive functional impairment and reduced quality of life. Beta-glucan possesses immunomodulatory and anti-inflammatory properties, but its therapeutic potential in COPD remains poorly defined. This study aimed to optimize a combined formulation of beta-glucan, broccoli extract, and quercetin (Pro β-Glucan+) through in vitro evaluation and to investigate its clinical efficacy in patients with stable COPD. Methods: HFL1 lung fibroblasts were treated with different ratios of Pro β-Glucan+®, and cell viability and wound healing assays were performed to identify the optimal formulation. The selected ratio was evaluated in a 12-week randomized, double-blind, placebo-controlled trial. A total of 42 participants were randomized, of whom 38 completed the study and were included in the final analysis (Pro β-Glucan+, n = 19; placebo, n = 19). Prespecified primary outcome was FEV ₁ . Secondary outcomes included clinical symptoms, functional capacity, health status, inflammatory and oxidative stress biomarkers, and patient satisfaction. Results: The 10:3:2 ratio (beta-glucan:broccoli extract:quercetin) significantly enhanced HFL1 cell cell viability and wound healing activity among the tested formulations and was selected for clinical evaluation. Pro β-Glucan+® was well tolerated and associated with within-group improvements in dyspnea, respiratory symptoms, functional capacity, and health status after 12 weeks, with significant between-group differences in mMRC and CAT scores at week 12. No significant within- or between-group difference was observed in the prespecified primary outcome, FEV ₁ , or in systemic inflammatory and oxidative stress biomarkers. Patient satisfaction was higher with Pro β-Glucan+® than with placebo. Conclusion: The optimized Pro β-Glucan+® formulation demonstrated in vitro biological activity and was associated with improvements in several clinical outcomes in patients with stable COPD. Significant between-group differences were observed in mMRC and CAT scores at week 12. These findings support further investigation of this combination as an adjunctive nutritional intervention for COPD management. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT05878834 , identifier NCT05878834.
SN - 1663-9812
ER -